-
Autor
Chen, Allen C 2 Arén Frontera, Osvaldo 1 Badin, Firas 1 Barrios, Carlos H 1 Barthélémy, Philippe 1 Bhagavatheeswaran, Prabhu 1 Blumenschein, George R 1 Borghaei, Hossein 1 Bracarda, Sergio 1 Carbone, David P 1 Castellano, Daniel 1 Chang, Han 1 Choueiri, Toni K 1 Ciuleanu, Tudor-Eliade 1 Corral Jaime, Jesus 1 Creelan, Benjamin 1 Doan, Justin 1 Donskov, Frede 1 Escudier, Bernard 1 Felip, Enriqueta 1
-
Pracoviště
Bristol Myers Squibb Princeton NJ 2 Aarhus University Hospital Aarhus Denmark 1 Antoni van Leeuwenhoek Ziekenhuis Amsterdam ... 1 Baptist Health Lexington Lexington KY 1 Barts Cancer Institute Cancer Research UK Ex... 1 Beth Israel Deaconess Medical Center Dana Fa... 1 British Columbia Cancer Agency Vancouver Canada 1 Centro Internacional de Estudios Clínicos Sa... 1 Centro de Pesquisa em Oncologia Hospital São... 1 Cleveland Clinic Taussig Cancer Institute Cl... 1 Davidoff Cancer Center Rabin Medical Center ... 1 Department of Thoracic Head and Neck Medical... 1 Duke University Durham NC 1 Fox Chase Cancer Center Philadelphia 1 From Memorial Sloan Kettering Cancer Center ... 1 From the Ohio State University Comprehensive... 1 H Lee Moffitt Cancer Center Tampa FL 1 Hollings Cancer Center Charleston SC 1 Hospital Universitario 12 de Octubre Madrid 1 Hospital Universitario Doce de Octubre Centr... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Motzer, Robert J
Autor Motzer, Robert J From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Tannir, Nizar M
Autor Tannir, Nizar M From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
McDermott, David F
Autor McDermott, David F From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Arén Frontera, Osvaldo
Autor Arén Frontera, Osvaldo From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Melichar, Bohuslav
Autor Melichar, Bohuslav From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Choueiri, Toni K
Autor Choueiri, Toni K From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Plimack, Elizabeth R
Autor Plimack, Elizabeth R From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Barthélémy, Philippe
Autor Barthélémy, Philippe From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
Porta, Camillo
Autor Porta, Camillo From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
-
George, Saby
Autor George, Saby From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma) Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.) Fox Chase Cancer Center, Philadelphia (E.R.P.) Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London Aarhus University Hospital, Aarhus, Denmark (F.D.) Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.) British Columbia Cancer Agency, Vancouver, Canada (C.K.K.) Westmead Hospital and Macquarie University, Sydney (H.G.) Jena University Hospital, Jena, Germany (M.-O.G.) Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.) Niigata University, Niigata, Japan (Y.T.) Hospital Universitario 12 de Octubre, Madrid (D.C.) Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.) Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.) and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.)
NLK
ProQuest Central
od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
PubMed
29562145
DOI
10.1056/nejmoa1712126
Knihovny.cz E-zdroje
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
- MeSH
- analýza přežití MeSH
- dospělí MeSH
- indoly aplikace a dávkování škodlivé účinky MeSH
- ipilimumab aplikace a dávkování škodlivé účinky MeSH
- karcinom z renálních buněk farmakoterapie mortalita MeSH
- kvalita života MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- monoklonální protilátky aplikace a dávkování škodlivé účinky MeSH
- nádory ledvin farmakoterapie MeSH
- přežití bez známek nemoci MeSH
- protinádorové látky imunologicky aktivní aplikace a dávkování škodlivé účinky MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- pyrroly aplikace a dávkování škodlivé účinky MeSH
- riziko MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Research Support, N.I.H., Extramural MeSH
- srovnávací studie MeSH
-
Carbone, David P
Autor Carbone, David P From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Reck, Martin
Autor Reck, Martin From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Paz-Ares, Luis
Autor Paz-Ares, Luis From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Creelan, Benjamin
Autor Creelan, Benjamin From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Horn, Leora
Autor Horn, Leora From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Steins, Martin
Autor Steins, Martin From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Felip, Enriqueta
Autor Felip, Enriqueta From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
van den Heuvel, Michel M
Autor van den Heuvel, Michel M From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Ciuleanu, Tudor-Eliade
Autor Ciuleanu, Tudor-Eliade From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
-
Badin, Firas
Autor Badin, Firas From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.) LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain H. Lee Moffitt Cancer Center, Tampa, FL (B.C.) Vanderbilt University Medical Center, Nashville (L. Horn) Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.) Baptist Health Lexington, Lexington, KY (F.B.) Duke University, Durham, NC (N.R.) Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.) Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.) Santa Maria Hospital, Terni, Italy (E.M.) Hollings Cancer Center, Charleston, SC (J.M.W.) Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.) Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.) and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.)
NLK
ProQuest Central
od 1980-01-03 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1980-01-03 do Před 3 měsíci
Family Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Psychology Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Health Management Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
Public Health Database (ProQuest)
od 1980-01-03 do Před 3 měsíci
PubMed
28636851
DOI
10.1056/nejmoa1613493
Knihovny.cz E-zdroje
BACKGROUND: Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC. METHODS: We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more. RESULTS: Among the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS: Nivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533 .).
- MeSH
- antigeny CD274 metabolismus MeSH
- lidé MeSH
- nádory plic chemicky indukované MeSH
- nemalobuněčný karcinom plic chemicky indukované MeSH
- přežití bez známek nemoci MeSH
- protinádorové látky * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.